Initiatives & Task Force Reports

ACNP Initiatives

ACNP Statement on Clinical Trials Registries (PDF 19Kb)

Through its official activities and the efforts of its membership, the College will work to ensure that the highest quality of science and ethics are integral to the conduct of clinical trials in our field.

Alcohol Clinical Trials Initiative (ACTIVE Workgroup) (PDF 58Kb)

The mission of this workgroup is to develop consensus reviews and recommendations to improve the design, execution, and interpretation of trials of medications for the treatment of alcohol dependence. It is not the intention of the group to propose standards that would be considered as requirements for the approval of product applications by regulatory agencies, but to advance the science of clinical trials in alcoholism treatment.

Bridging the Gap with Clinical and Translational Science Awards (CTSA)

The ACNP Liaison Committee has been working to determine how the College can assist in the effort to ensure that the neuropsychiatric research community can become more involved with CTSAs and utilize the capabilities associated with CTSAs. The attached slide set is for members to familiarize themselves with this effort and to utilize this mechanism to foster neuropsychiatric research programs specifically, as there are very few CTSAs that presently have a psychiatric focus. Click here to see a listing of ACNP Members at CTSA Institutions

Code of Conduct for Supporting Corporations (PDF 25Kb)

In April 2006, The American College of Neuropsychopharmacology (ACNP) Council endorsed this Code of Conduct for its supporting corporations and their designated representatives.

Roles and Responsibilities for Supporting Corporations (PDF 27Kb)

The ACNP has committed itself to establish effective, collaborative relationships with patient advocacy organizations, government, academia, and industry that help to advance the scientific goals of the College, and to serve as a catalyst for collaborative work to advance discovery and disseminate scientific advances.

Task Force Reports

ACNP Statement to IOM Committee on the Assessment of US Drug Safety System

Presented by Donald F. Klein, MD

ACNP Task Force on Industry Publications Report to Council (PDF 5390Kb)

Council appreciates the work done by the Task Force on Industry Publication in preparing this report. The report is being made available only to ACNP members for their review. Members may want to share their comments on the report with Council. That can be done by sending an email to acnp@acnp.org and indicate “Comments on report on industry publication” in the email subject line.
Source: ACNP Task Force on Industry Publications

Annual Meeting Task Force Report

Qualitative and Quantitative Research to Gather Data from the ACNP Membership on the Content, Structure, Time, and Location of the Annual Meeting
Source: Innovation Management
Apr 2, 2007

SSRIs and Suicide in Youth

ACNP Task Force Report on SSRIs and Suicidal Behavior in Youth

Task Force Report on Terrorism (PDF 91Kb)

The impact of terrorism on brain and brain behavior: What we know and what we need to know
Apr 21, 2004

Use of Antipsychotic Drugs (PDF 177Kb)

ACNP White Paper: Update on Use of Antipsychotic Drugs in Elderly Persons with Dementia
Source: Neuropsychpharmacology (2007), 1-14

User Name:
Password:

Forgot your user name or password?
Remember me.